Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies.

Literature DB >> 26140429

The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies.

T Dosani, M Carlsten, I Maric, O Landgren.

Abstract

Entities: Disease

Year: 2015 PMID： 26140429 PMCID： PMC4526775 DOI： 10.1038/bcj.2015.49

Source DB: PubMed Journal: Blood Cancer J ISSN： 2044-5385 Impact factor: 11.037

× No keyword cloud information.

Correction to: Blood Cancer Journal (2015) 5, e306; doi:10.1038/bcj.2015.32; published online 17 April 2015 Since the publication of this paper, the authors have noticed an error in the title. It should read ‘The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma and their uses in immunotherapies'. This paper has now been corrected.

10 in total

1. Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.

Authors: Michal Bar-Natan; Dina Stroopinsky; Katarina Luptakova; Maxwell D Coll; Arie Apel; Hasan Rajabi; Athalia R Pyzer; Kristen Palmer; Michaela R Reagan; Myrna R Nahas; Rebecca Karp Leaf; Salvia Jain; Jon Arnason; Irene M Ghobrial; Kenneth C Anderson; Donald Kufe; Jacalyn Rosenblatt; David Avigan
Journal: Br J Haematol Date: 2017-01-20 Impact factor: 6.998

2. Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma.

Authors: Matevz Skerget; Barbara Skopec; Darja Zontar; Peter Cernelc
Journal: Radiol Oncol Date: 2016-05-12 Impact factor: 2.991

Review 3. Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.

Authors: Masafumi Taniwaki; Mihoko Yoshida; Yosuke Matsumoto; Kazuho Shimura; Junya Kuroda; Hiroto Kaneko
Journal: Mediterr J Hematol Infect Dis Date: 2018-02-15 Impact factor: 2.576

Review 4. Biological determinants of health disparities in multiple myeloma.

Authors: Cheryl Jacobs Smith; Stefan Ambs; Ola Landgren
Journal: Blood Cancer J Date: 2018-08-28 Impact factor: 11.037

5. Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.

Authors: Sundar Jagannath; Jacob Laubach; Ellice Wong; Keith Stockerl-Goldstein; Cara Rosenbaum; Madhav Dhodapkar; Ying-Ming Jou; Mark Lynch; Michael Robbins; Suresh Shelat; Kenneth C Anderson; Paul G Richardson
Journal: Br J Haematol Date: 2018-05-29 Impact factor: 6.998

6. Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies.

Authors: Taxiarchis V Kourelis; Jose C Villasboas; Erik Jessen; Surendra Dasari; Angela Dispenzieri; Dragan Jevremovic; Shaji Kumar
Journal: Blood Cancer J Date: 2019-08-28 Impact factor: 11.037

The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies.

1. Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.

2. Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma.

Review 3. Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.

Review 4. Biological determinants of health disparities in multiple myeloma.

5. Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.

6. Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies.

Review 7. Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma.

8. Development of [⁸⁹Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma.

Review 9. NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias.

Review 10. Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma.

The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies.

1. Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.

2. Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma.

Review 3. Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.

Review 4. Biological determinants of health disparities in multiple myeloma.

5. Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.

6. Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies.

Review 7. Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma.

8. Development of [89Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma.

Review 9. NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias.

Review 10. Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma.

8. Development of [⁸⁹Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma.